About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 7, 2026) - BioHarvest Sciences Inc., (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today issued a letter to shareholder partners from Chief Executive Officer, Ilan Sobel.Dear Fellow Shareholders,2025 marked an important milestone for BioHarvest Sciences: our first full year as a NASDAQ-listed company, and we enter 2026 with an annualized revenue ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 18, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that it has been awarded a $1.6 million grant from the Israeli Innovation Authority (IIA). The grant was approved under the IIA's Bio-Convergence program, which supports technologies at the intersection of biology, engineering, data science ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - BioHarvest Sciences Inc. has launched VINIA Blood Flow Hydration™, the first hydration solution utilizing VINIA's Piceid resveratrol technology, entering the $13 billion U.S. electrolyte market [1][2][15] - The product aims to enhance hydration by improving blood flow, thereby facilitating more efficient delivery of fluids and electrolytes to the body [2][6][12] Product Overview - VINIA Blood Flow Hydration™ is designed to improve circulation and hydration, combining water, electrolytes, and red grape powder to enhance nutrient delivery [7][12] - The formulation includes 470 mg of sodium, 190 mg of potassium, and 80 mg of magnesium per serving, along with 6 mg of rapid absorption Piceid resveratrol [11][12] - The product is available in six flavors: Mixed Berry, Fruit Punch, Watermelon, Summer Orange, Lemonade, and Lemon Lime, developed by a former Coca-Cola flavor formulator [10][11] Market Strategy - The product is exclusively available at Vinia.com with free delivery across North America and will also be sold on Amazon by the end of December [15] - BioHarvest aims to differentiate itself in the hydration market by leveraging superior science, efficacy, and taste, targeting high double-digit revenue growth [7][15] Consumer Assurance - BioHarvest offers a 90-Day "Feel It or It's Free" guarantee, allowing customers to return the product if they are not satisfied [14] - Each batch of VINIA Blood Flow Hydration™ is tested for banned substances under the Informed Sport program, ensuring safety for athletes [13]

分组1 - BioHarvest Sciences Inc. reported a quarterly loss of $0.14 per share, which is an improvement from a loss of $0.16 per share a year ago, aligning with the Zacks Consensus Estimate [1] - The company posted revenues of $9.07 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.74%, but showing an increase from $6.54 million year-over-year [2] - The stock has increased approximately 27.8% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] 分组2 - The earnings outlook for BioHarvest Sciences Inc. is uncertain, with current consensus EPS estimates at -$0.09 for the coming quarter and -$0.59 for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - The estimate revisions trend for BioHarvest Sciences Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it will perform in line with the market [6]

Financial Data and Key Metrics Changes - Total revenues increased 39% year-over-year to $9.1 million in Q3 2025, compared to $6.5 million in Q3 2024 [3][13] - Gross profit increased 50% to $5.6 million, representing 61% of total revenue, up from 57% in the same year-ago quarter [13][14] - Adjusted EBITDA loss narrowed to $0.4 million in Q3 2025 from a loss of $1.7 million in Q3 2024 [14] Business Line Data and Key Metrics Changes - Product revenue grew 30% to $8.4 million, while CDMO revenue surged 722% to $0.7 million [13][14] - Core capsules accounted for 88% of product revenues, with new products contributing approximately 30% of growth [4][5] Market Data and Key Metrics Changes - The US VINIA active user base exceeded 75,000 customers, contributing to revenue growth [3] - The launch of VINIA BloodFlow Hydration targets the $17 billion US electrolyte hydration market [9] Company Strategy and Development Direction - The company operates two business verticals: direct-to-consumer products and CDMO services, aiming to drive revenue from both branded products and B2B partnerships [4] - The recent capital raise of $19.9 million will fund the next growth phase, including tripling manufacturing capacity and expanding CDMO services [11][12] - The company aims to achieve adjusted EBITDA break-even by early 2026, with a focus on revenue growth and margin improvement [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive adjusted EBITDA soon, emphasizing the importance of scaling operations and maintaining cost discipline [15][17] - The company is focused on executing the rollout of new products and expanding its Health Pros Affiliate Program to enhance customer acquisition [16][17] Other Important Information - The company secured a new CDMO partnership with SaffronTech to develop saffron-derived compounds, retaining a 25% ownership of the resulting product [5][6] - Gross profit margins improved due to increased manufacturing scale and improved yields [14] Q&A Session Summary Question: Expectations for the ramp-up of the new hydration product - Management indicated a staged launch with initial positive responses and expects a quarter-on-quarter ramp-up in sales, particularly after the broader launch on December 3 [19][22] Question: Update on CDMO opportunities and SaffronTech agreement - Management detailed the collaboration with SaffronTech, emphasizing a fast-tracked development process and the potential for a quick market entry [24][26] Question: Progress on existing CDMO contracts - Management provided updates on ongoing CDMO agreements, highlighting progress in the cosmetic fragrance space and the Tate & Lyle agreement [32][33] Question: Long-term outlook for CDMO business - Management projected that by 2027-2028, approximately 75% of revenue could come from the CDMO business, with margins significantly higher than the product business [47][49] Question: Early success with the HealthPros program - Management reported strong early engagement and conversion rates from HealthPros, with plans to onboard 300 professionals by year-end [41][43]

Group 1 - Proactive specializes in providing fast, accessible, and actionable business and finance news content to a global investment audience [2][3] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team operates from key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2][3] Group 2 - Proactive is committed to technology adoption, utilizing various tools to enhance workflows and content production [4][5] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Financial Performance - For the nine-month period ended September 30, 2025, the company reported revenues of $25,442,000, a 42% increase compared to $17,910,000 for the same period in 2024[6] - The gross profit for the nine-month period was $15,251,000, representing a 55% increase from $9,819,000 in the prior year[6] - Operating loss for the nine-month period was $4,454,000, a decrease from $5,302,000 in the same period of 2024[6] - The Company incurred a net loss of $2,513 for the three months ended September 30, 2025, and a comprehensive loss of $8,931 for the nine months ended September 30, 2025[87][89] - The Company recognized a segment loss of $4,454 for the nine months ended September 30, 2025, with the Products segment loss at $4,051 and CDMO Services at $403[89] Cash Flow and Liquidity - The company had cash and cash equivalents of $10,966,000 as of September 30, 2025, significantly up from $2,390,000 at the end of 2024[4] - The company incurred negative cash flows from operating activities of $4,974,000 for the nine-month period ended September 30, 2025[12] - The net proceeds from the Equity Offering and other events are expected to significantly strengthen the Company's liquidity position and support ongoing operations[25] Equity and Financing - The company completed an equity offering in September 2025, resulting in net proceeds and debt reduction of approximately $14,202,000[22] - The Company completed a Public Offering on November 10, 2025, resulting in gross proceeds of approximately $19.93 million and net proceeds of approximately $18.44 million after deductions[24] - The Company borrowed $1.68 million from private investors during the nine-month period ended September 30, 2025, with interest rates of 16% and 20%[52] - The outstanding balance of short-term loans as of September 30, 2025, is $3.08 million, with $678,000 at a 16% interest rate and $2.40 million at a 20% interest rate[52] - The Company issued 1,146,474 common shares as a result of the conversion of convertible loans, increasing share capital by $7.09 million[43] - The Company extended 503,033 Early Conversion Warrants and 257,143 Major Investor Warrants for an additional 24 months as part of its financing strategy[60] Revenue Segmentation - For the nine months ended September 30, 2025, total revenues were $25,442, with the Products segment at $24,134 and CDMO Services at $1,308[89] - For the three months ended September 30, 2025, external revenue from North America was $7,836 million, compared to $6,009 million in 2024, indicating an increase of 30.4%[96] - For the nine months ended September 30, 2025, external revenue from North America was $22,609 million, up from $16,321 million in 2024, representing a growth of 38.5%[91] - The Company has no single customer contributing 10% or more of total revenue for the three and nine months ended September 30, 2025, and 2024[92] Assets and Deficits - The company's accumulated deficit as of September 30, 2025, reached $105,349,000, up from $96,418,000 at the end of 2024[4] - The total assets increased to $35,188,000 as of September 30, 2025, compared to $25,001,000 at the end of 2024[4] Operational Focus - The Company is focused on developing therapeutic solutions using its Botanical Synthesis Platform Technology, which allows for the production of active ingredients without traditional agriculture[19] - The Company has not experienced any material impact on operations due to recent geopolitical events as of the date of the financial statements[31] Shareholder Actions - As of September 30, 2025, the Company issued and outstanding common shares increased to 19,616,380 from 17,327,716 as of December 31, 2024[42] - The Company granted 78,712 options at an exercise price of $9.00 and 18,572 options at $8.30 during the period, with total values of $284 and $79 respectively[48] - The exercise price of certain warrants was reduced from $7.77 and $11.52 to $6.50 per share as part of the Equity Offering[43] - The Company issued 1,786 common shares on October 14, 2025, from employee and consultant options, generating proceeds of $9 million[96] - Following September 30, 2025, the Company issued 189,279 common shares from warrant exercises, resulting in proceeds of $1,108 million[96]